Expert opinion on drug metabolism & toxicology
The most recent articles from:
August 2013
-
Expert Opin Drug Metab Toxicol · Aug 2013
ReviewPharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012. Its primary mode of action is inhibition of dihydroorotate dehydrogenase which inhibits the proliferation of activated T cells, but it also has a number of other actions that may be important contributors to its efficacy in MS. ⋯ While teriflunomide is no more effective than a number of other agents that are used in the treatment of MS, it has a favorable side-effect profile and the convenience of once a day oral administration. As such, it is likely to be a popular agent in the treatment of MS over the next 5 years.